Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Invested Capital (2020 - 2025)

Keros Therapeutics' Return on Invested Capital history spans 5 years, with the latest figure at 0.13% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 51.0% year-over-year to 0.13%; the TTM value through Dec 2025 reached 0.13%, up 51.0%, while the annual FY2025 figure was 0.15%, 61.0% up from the prior year.
  • Return on Invested Capital reached 0.13% in Q4 2025 per KROS's latest filing, up from 0.06% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.13% in Q4 2025 to a low of 0.4% in Q3 2022.
  • Average Return on Invested Capital over 4 years is 0.19%, with a median of 0.24% recorded in 2021.
  • Peak YoY movement for Return on Invested Capital: plummeted -102bps in 2021, then surged 51bps in 2025.
  • A 4-year view of Return on Invested Capital shows it stood at 0.25% in 2021, then tumbled by -57bps to 0.4% in 2022, then increased by 4bps to 0.38% in 2024, then soared by 133bps to 0.13% in 2025.
  • Per Business Quant, the three most recent readings for KROS's Return on Invested Capital are 0.13% (Q4 2025), 0.06% (Q3 2025), and 0.0% (Q2 2025).